Mantle Cell Lymphoma (MCL) Completed Phase 2 Trials for Bendamustine (DB06769)

Also known as: Lymphoma, Mantle-Cell / Mantle Cell Lymphoma / Mantle-Cell Lymphoma / Lymphoma, Mantle- Cell / Lymphoma, Mantle Cell / Mantle-Cell Lymphomas / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS / Mantle cell lymphomas

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00992134Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell LymphomaTreatment
NCT01737177Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCLTreatment
NCT00891839Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell LymphomaTreatment
NCT01662050Phase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCLTreatment
NCT00612183Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell LymphomaTreatment